EHA 2024: Updates in the Treatment of CLL : Episode 11

Opinion

Video

August 5, 2024

Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

Author(s):

Catherine C. Coombs, MD,Matthew S. Davids, MD, MMSc

Experts analyze recent real-world evidence on treatment patterns, focusing on the strategies and outcomes of switching and sequencing therapies in chronic lymphocytic leukemia patients.

EP: 1.Introducing the Expert Panel on CLL Treatment Updates Live at EHA 2024

EP: 2.Testing Practices and Role of High-risk Features to Decision Making in Newly Diagnosed CLL

EP: 3.Frontline BTKi Selection

EP: 4.Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

EP: 5.Dr Lamanna Reviews Study Data for 1L Doublet Therapy or Triplet Therapy

EP: 6.Dr Danilov Reviews EHA 2024 Data on the Role of 1L Triplet Therapy in CLL

EP: 7.EHA 2024 Review of Ongoing Trials Evaluating BCL2i/BTKi Combination Approaches

EP: 8.Navigating Treatment Approaches for R/R CLL

EP: 9.How Experts View MAIC Data That was Presented at EHA 2024

EP: 10.BTKi Intolerance in Real-world Practice & Management Strategy

Now Viewing

EP: 11.Applying EHA 2024 Data to Switching and Sequencing Treatments for CLL & Impact of Toxicities

EP: 12.Approach to Hypertension Management With BTKi Treatment

EP: 13.Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib

EP: 14.Navigating BTKi Resistance in CLL with Findings from ELEVATE-RR and ALPINE Studies: Sequencing Approach and Potential Role for Testing

EP: 15.Experts Review Pirtobrutinib Clinical Data and Share its Utilization in Practice

EP: 16.TRANSCEND CLL 004 Data Review and its Impact on Future Treatment Practices

EP: 17.EHA 2024 Updated Data on BTKi Degraders as Emerging Novel Agents in R/R CLL

EP: 18.Dr Parrando Reviews EHA 2024 Data on BTKi Degrader, BGB-16673

EP: 19.Dr Lamanna Shares Perspectives on EHA 2024 Data for the 2G BCL2 Inhibitors in R/R CLL

EP: 20.Review of Data from EHA 2024 of Emerging Novel Bispecific Antibodies

EP: 21.Clinical Pearls and Impacts to Practice from EHA 2024

Briefly comment on recent real world data regarding switching and sequencing to next line of therapy in patients with CLL. (Pinilla-Ibarz, et al. EHA 2024. Abstract P697)
How do you interpret these data and how may they influence your overall treatment approach?